Targeting and cytotoxicity of chimeric antigen receptor T cells grafted with PD1 extramembrane domain.

ABSTRACT:

Background

Immunosuppression induced by programmed cell death protein 1 (PD1) presents a significant constraint on the effectiveness of chimeric antigen receptor (CAR)-T therapy. The potential of combining PD1/PDL1 (Programmed cell death 1 ligand 1) axis blockade with CAR-T cell therapy is promising. However, developing a highly efficient and minimally toxic approach requires further exploration. Our attempt to devise a novel CAR structure capable of recognizing both tumor antigens and PDL1 encountered challenges since direct targeting of PDL1 resulted in systemic adverse effects.

Methods

In this research, we innovatively engineered novel CARs by grafting the PD1 domain into a conventional second-generation (2G) CAR specifically targeting CD19. These CARs exist in two distin

SUBMITTER: Zhang A 

PROVIDER: S-EPMC10543853 | biostudies-literature | 2023 Sep

REPOSITORIES: biostudies-literature